Vertex Pharmaceuticals cleared major regulatory hurdles to acquire Crinetics Pharmaceuticals. The U.S. Hart-Scott-Rodino waiting period expired on August 12, 2026. Regulators in Austria, Germany, and Australia also granted antitrust approvals.
The transaction carries an approximate value of $10 billion. Vertex first announced the acquisition on July 6, 2026.
Crinetics shareholders will vote on the merger during a special meeting on August 28, 2026. The companies expect the deal to close in early September 2026.